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1. INTRODUCTION 
Colicin E3 is a plasmid ColE3-CA38directed 
antibacterial protein composed of two polypep- 
tides, protein A and protein B of M, 61000 and 
10000, respectively [1,2]. After colicin E3 is ad- 
sorbed onto receptors in the outer membrane of 
sensitive cells, it finally inactivates ribosomes by 
cleaving the 16 S RNA in the 30s subunit at a 
specific site [3,4]. This ribonuclease activity is ex- 
clusively attributed to the T2A domain, the C- 
terminal part of protein A. Tryptic digestion of in- 
tact colicin E3 (i.e., the AB complex) gives the Tl 
fragment and the T2 complex. This complex con- 
sists of the active fragment T2A and the inhibitor 
protein B [5,6]. Models similar to the above have 
been proposed for colicin E2 and cloacin DF13 
[7,8]. The inhibitor protein acts specifically on 
each bacteriocin, and is produced in a greater 
quantity than bacteriocin, and in this way may pro- 
tect the host cell from lethality. Consequently, the 
inhibitor protein is usually referred to as ‘an im- 
munity protein’ or ‘an immunity substance’ 
[1,9-121. Here, however, we simply refer to it as 
‘protein B’. The amino acid sequences of E3-T2A 
fragment [13], E3-protein B [14] and DF13- 
immunity protein [15] have been reported. 
or E3 seems to function adequately in both the in- 
duced and non-induced states (unpublished). Our 
attention has been directed toward the mechanisms 
of expression and regulation of colicinogenicity 
and immunity. Although recent studies have 
shown some of the details involved in molecular 
structures of colicin E2 and E3, little is known 
regarding the genetic constructions of ColE2-P9 
and ColE3-CA38 plasmids. 
We now report the location and the nucleotide 
sequence of the DNA region encoding protein B 
and the T2A domain of protein A of colicin E3. 
2. METHODS 
All the plasmids were prepared by the method of 
[ 181. ColE3-CA38 was isolated from E. co/i RR1 
(ColE3-CA38), which was obtained by transform- 
ing RR1 [19] with the plasmid fraction prepared 
from W3 110Str’ (ColE3, COB-CA38) [20]. 
Once these bacteriocinogenic ells are treated by 
ultraviolet irradiation or with chemicals such as 
mitomycin C, ‘SOS functions’ are induced and the 
cells begin to produce a large number of bacterio- 
tin molecules as well as free protein B molecules 
[9,16,17]. The production of protein B is thus in- 
ducible; nonetheless, immunity toward colicin E2 
The 2.8 kilobase PvuII-HincII fragment derived 
from ColE3-CA38 was inserted between the PvuII 
and NincII (in the tet gene) sites of pBR328 [19], 
giving rise to a recombinant plasmid pSH302. This 
plasmid confers both colicinogenicity and immuni- 
ty on the host cell. That is, the intact colicin E3 
gene must be carried on this PvuII-NincII frag- 
ment (fig. la; details of derivation and 
characterization of pSH302 and the related 
plasmids are reported elsewhere). 
The 5’-end-labelled DNA fragments were pre- 
pared and sequenced as in [21]. The fine restriction 
map was made according to [22]. 
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3. RESULTS AND DISCUSSION 
Watson and Visentin reported the restriction 
maps of ColE2-P9 and ColE3-CA38, and showed 
that these plasmids have homologous restriction 
sites except for two non-homologous regions, 
Bgfl-PvuI and PvuII-SmaI [23]. The 2.8 kilobase 
PvuII-HincII fragment of our plasmid pSH302 
contains this PvuII-SmaI segment and a short 
SmaI-HincII segment (fig. la). We found another 
restriction site C/a1 at the center of the 
PvuII-SmaI segment in both ColE2-P9 (not 
shown) and ColE3-CA38, so that the non- 
homologous region on PvuII-SmaI was restricted 
to PvuII-C/a1 (fig. la). This finding is consistent 
with the result obtained from a heteroduplex ex- 
periment of ColE2-P9 and ColE3-CA38 [25]. We 
estimated the protein A-coding region of 
ColE3-CA38 to be 1.6-l .7 kilobase long (from M, 
-61000) and the number of amino acids (-582) of 
protein A [2]. In serological and functional 
aspects, the protein A molecules of colicin E2 and 
colicin E3 were shown to be the same except in the 
C-terminal region [2,24]. Based on the above 
results, we assumed that the C-terminal part of 
ColE3-CA38 protein A might be encoded within 
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Fig. la) Restriction map of the 2.8 kilobase (kb) 
PvuII-Z-Zinc11 fragment of pSH302. The DNA 
fragments derived from ColE3-CA38 and pBR328 are 
shown with an open box and solid lines, respectively. 
The restriction sites are indicated as follows: PvuII(P), 
XhoI(X), EcoRI(E), &MI(K), &n(B), C/uI(C), 
SmaI(SI), HincII(HII), AM(A), Sau3AI(S3), Hin- 
fI(Hf). (b) The strategy used for sequencing. Arrows in- 
dicate the direction and extend of DNA sequences deter- 
mined. (c) The arrangement of genes A and B identified 
in this work. 
the PvuII-C&I segment. Thus, we made a fine 
restriction map of this region (fig. la), and se- 
quenced DNA fragments in order to identify the 
structural genes of protein A (gene A) and protein 
B (gene B) of colicin E3 (fig. lb). 
Fig. 2 shows the nucleotide sequence of 600 
basepairs beginning at the position -200 basepairs 
away from the ClaI site toward the PvuII site. In 
the region from the position 34-321, we found an 
open reading frame compatible with the amino 
acid sequence of the T2A fragment determined in 
[131. 
Moreover, another reading frame (334-588) was 
found to start at a point only 9 bases downstream 
from the termination codon of gene A. This frame 
was compatible with the amino acid sequence of 
protein B determined in [14] except for one amino 
acid residue (no. 45), so that this region was con- 
cluded to be gene B. The Asp at residue 45 propos- 
ed in [14] may have originated in E. coli cells from 
some post-translational modification of Asn-45 in 
our data. 
Thus, genes A and B face the same direction and 
must be co-ordinately transcribed. We identified a 
candidate sequence for the promoter of gene A 
(and gene B) that possibly responds to ‘SOS func- 
tions’ near the SmaI site of pSH302 (experiments 
for verification of this now in progress). However, 
we also found possible promoter sequences at the 
center of the T2A-coding region; TTCTCA 
(198-203) and TATCGTG (223-229) may be ‘the 
-35 region’ and ‘Pribnow box’, respectively [26]. 
However, we have no evidence to show that they 
actually function. 
The sequence GAGG (325-328) in the interven- 
ing space probably serves as a ribosome binding 
site [27]. This suggests that the translation of gene 
B does not depend on that of gene A. Alternative- 
ly, it is also possible that the translation continues 
into gene B immediately following the termination 
of gene A. These two possibilities seem to support 
the observation that protein B is produced in two 
different states in cells treated with mitomycin C: 
the AB complex and the free protein B [1,9,12]. 
The nucleotide sequence of CloDF13 immunity 
gene and the amino acid sequence of DF13-im- 
munity protein was determined in [15]. The amino 
acid sequence of E3-protein B was also deduced 
from the partial sequence determination and the 
amino acid analysis of the tryptic peptides, and E3- 
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r+ T2A 50 100 
[ColE3-CA381 AATTTAAAC~ATGAAAAGPT~GCCCA~GGTTTT~GATTACG~GCAT~TTA~CATCCAGCT~CG~CT~G~TATTA~GGGCTTGGT~ 
AsnLeuAsnAspGluLysAsnLysProArgLysGlyPheLysAspTyrGlyHisAspTyrHisProAlaProLysThrGl~snIleLysGlyLeuGly 
150 200 
ATCTTAAGC~TGGGATACCAAAAACACCAAAGCAGAATG~TGGTG~CGC~GCGC~G~CTG~~TA~GGGCG~~GATTTAT~GTGG~TT~ 
AspLeuLysProClyIleProLysThrProLysGl~snGl~lyGlyLysArSLysArSTrpThrGlyAspLysGlyArSLysIleTyrGluTrpAspSe~ 
250 300 
TCAGCATGGiGAGCTTGAG;GGTATCGTGtCAGTGATGG~CAGCATCTT;;GCTCATTTGCCCT~C~GGCAATCAG~TGA~GGTC~AGATCCGAP;\ 
GlnHisGlyGluLeuGluGlyTyrArgAlaSerAspGlyGlnHisLeuGlySerPheAspProLysThrGlyAsnGlnLeuLysGlyProAspProLys 
[CloDF131 ~GATCCbA 
(AspProLys 
I+6 350 400 
CGAAATATC;\AGAAATATC;TTGAGAGGA;GTTATGGGA~TT~TTG~TTT~CTTG~TTTGAT~~GTACAG~G~TTTT~GGG~~GGAGTAT~ 
ArSAsnIleLysLysTyrLeu f~tGlyLeuLysLeuAspLeuThrTrpPheAspLysSerThrGluAspPheLysGlyGluGluTyr 
CGAAA*CAT;A~TATCTTT~GAGG~~TATGGG*T 
ArgAsnIleLysLysTyrLeu) f~tGlyLeuLysLeuHisIleHisTrpPheAspLysLysThrG1uGluPheLysGly~GluTyr 
amino acid residue No.1 10 - - 20 
450 500 
CAAAAGATT;TGGAGATGA~GGTTCAGTT;\TGGAAAGTC~AGGTGTGCC~TTT~G~T~TGTT~T~CGGTTGCTT~GATGTTATA~CTG~TGGG~ 
SerLysAspPheGlyAspAspGlySerVal~tGluSerLeuGlyValProPheLysAspAsnValAs~snGlyCysPheAspValIleAlaGluTrpVal 
CAAAAW\*CTT*CGG;GATGA;GGTTC;GT*CAT;GAAAGTGCCTTT~GGATAAT~TTAATAA;GGTTG*GTTTGATGTT*~~ATGGGT 
SerLysAspPheGlyAspAspGlySerValIleGluSerLeuGly~ProLeuLysAspAsn~As~snGly~PheAspValGluLy~Pr~TrpVal 
30 - -40 50 
550 600 
ACCTTTGCT~CAACCATAC;TTAATCATCAAATTGATAT;TAT~ 
ProLeuLeuGlnProTyrPheAsnHisGlnIleAspIleSerAspAsnGluTyrPheValSerPheAspTyrArgA~pGlyAspTrp 
** ** ** 
TTCGATATTACA~CCA*CACTTT~T*G;AAT*CGATATT~*~~T~~TA~TTTGT~TC~TTTG~~A~CG*~TGGT~TGGT~C~~ 
SerIleLeuGlnProHisPheLy~snValIleAspIleSerLysPh~spTyrPheValSerPheV8lTyrAr~~pGlyAsnTrp 
60- - 76 -so = 
Fig. 2. Nucleotide and amino acid sequences of gene B and the latter part of gene A of ColE3-CA38, aligned with those 
of CloDFl3 [ 151. Replacements of nucleotides (*) and amino acids (= and -) between the two plasmids are shown 
along the CloDF13 sequences; (=): replacements involving a change in charge; (-) the other replacements. 
protein B compared with DF13-immunity protein 
[ 151. Our sequence data on ColE3-CA38 gene B 
differ from those in [15] on E3-protein B in 24 out 
of 84 amino acid residues, and consequently, the 
gross profile of protein B assumed on the basis of 
our data is not the same as that proposed for E3- 
protein B in [15]: 
(i) Residue 12 is not Lys but Ser in our data, and 
thus the methylation of this residue mentioned 
in [15] is not likely to occur in colicin E3. 
(ii) According to [ 151, 18 differences were found 
between the amino acid sequences of E3- 
protein B and DF13-immunity protein, and 
these residues seem dispersed throughout all 
the molecules. Our data show that there are 25 
differences, and that major replacements occur 
within the latter halves of the molecules. 
In spite of the above replacements, there is con- 
siderable homology between colicin E3 and cloacin 
DF13 in both amino acid and nucleotide se- 
quences. We found that this homologous region 
extends upstream from the termination of gene A 
through 30 nucleotides reported in [ 151. Following 
termination of gene B, there are about 70 other 
131 
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homologous nucleotides (not shown). The high 
homology in the amino acid sequence of gene B 
(71%) is comparable to that in the nucleotide se- 
quence (73%) and implies that some requirement 
of amino acids might serve as a selective pressure 
in evolution. From this point of view, the codon- 
usage of Ser-69 is of interest; the TCC codon is 
used in ColE3-CA38 and the AGT in CloDF13. 
Colicin E3 and cloacin DF13 are homologous 
bacteriocins with respect to both structure and 
mode of action, but protein B inhibits specifically 
the ribosome-inactivating activity of each protein 
A [17]. Here, we show that the homology between 
the two plasmids further extends to gene arrange- 
ment and nucleotide sequence. In addition, some 
differences between two protein B regions may 
possible provide an explanation for the highly 
specific inhibitor activities. 
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